BR9907691B1 - derivado de antìgeno e antìgeno da famìlia mage associado a tumor, seqüência de ácido nucléico, codificando os mesmos, seus usos na preparação de vacina, processo para produção de vacina e vacina. - Google Patents

derivado de antìgeno e antìgeno da famìlia mage associado a tumor, seqüência de ácido nucléico, codificando os mesmos, seus usos na preparação de vacina, processo para produção de vacina e vacina.

Info

Publication number: BR9907691B1
Authority: BR; Brazil
Prior art keywords: vaccine; antigen; tumor; coding; derived
Prior art date: 1998-02-05

Application number

BRPI9907691-8A

Other languages

English (en)

Other versions

BR9907691A (pt

Inventor

Teresa Cabezon Silva

Joseph Cohen

Moncef Mohamed Slaqui

Carlota Vinals Bassols

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-02-05

Filing date

1999-02-02

Publication date

2011-05-31

1998-02-05 Priority claimed from GBGB9802543.0A external-priority patent/GB9802543D0/en

1998-02-06 Priority claimed from GBGB9802650.3A external-priority patent/GB9802650D0/en

1999-02-02 Application filed filed Critical

2000-11-14 Publication of BR9907691A publication Critical patent/BR9907691A/pt

2011-05-31 Publication of BR9907691B1 publication Critical patent/BR9907691B1/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
- C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Immunology (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Zoology (AREA)
Mycology (AREA)
Microbiology (AREA)
Oncology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Marine Sciences & Fisheries (AREA)
Communicable Diseases (AREA)
Pulmonology (AREA)
Toxicology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

BRPI9907691-8A 1998-02-05 1999-02-02 derivado de antìgeno e antìgeno da famìlia mage associado a tumor, seqüência de ácido nucléico, codificando os mesmos, seus usos na preparação de vacina, processo para produção de vacina e vacina. BR9907691B1 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB9802543.0A GB9802543D0 (en)	1998-02-05	1998-02-05	Vaccine
GBGB9802650.3A GB9802650D0 (en)	1998-02-06	1998-02-06	Vaccine
PCT/EP1999/000660 WO1999040188A2 (en)	1998-02-05	1999-02-02	Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccinations

Publications (2)

Publication Number	Publication Date
BR9907691A BR9907691A (pt)	2000-11-14
BR9907691B1 true BR9907691B1 (pt)	2011-05-31

Family

ID=26313069

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI9907691-8A BR9907691B1 (pt)	1998-02-05	1999-02-02	derivado de antìgeno e antìgeno da famìlia mage associado a tumor, seqüência de ácido nucléico, codificando os mesmos, seus usos na preparação de vacina, processo para produção de vacina e vacina.

Country Status (25)

Country	Link
US (3)	US8097257B2 (pt)
EP (4)	EP1659179B1 (pt)
JP (2)	JP4768121B2 (pt)
KR (2)	KR100824105B1 (pt)
CN (1)	CN1227360C (pt)
AR (1)	AR018064A1 (pt)
AT (4)	ATE462788T1 (pt)
AU (1)	AU737337B2 (pt)
BR (1)	BR9907691B1 (pt)
CA (2)	CA2584482C (pt)
CY (4)	CY1105685T1 (pt)
CZ (2)	CZ298364B6 (pt)
DE (3)	DE69943359D1 (pt)
DK (4)	DK1584685T3 (pt)
ES (2)	ES2255248T3 (pt)
HU (1)	HU228467B1 (pt)
IL (4)	IL137442A0 (pt)
NO (2)	NO328507B1 (pt)
NZ (1)	NZ506086A (pt)
PT (4)	PT1053325E (pt)
SA (1)	SA99200126B1 (pt)
SI (4)	SI1584685T1 (pt)
TR (1)	TR200002284T2 (pt)
TW (1)	TWI238853B (pt)
WO (1)	WO1999040188A2 (pt)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1227360C (zh)	1998-02-05	2005-11-16	史密丝克莱恩比彻姆生物有限公司	Mage家族肿瘤相关抗原衍生物及其编码核酸序列
EP1502602A3 (en) *	1998-10-05	2006-05-17	Pharmexa A/S	Methods for therapeutic vaccination
DE69918146T2 (de)	1998-10-05	2005-07-07	Pharmexa A/S	Verfahren zur therapeutischen impfung
GB9908885D0 (en) *	1999-04-19	1999-06-16	Smithkline Beecham Biolog	Vccine
PT1650221E (pt)	2000-02-23	2012-09-05	Glaxosmithkline Biolog Sa	Novos compostos
ES2309064T3 (es) *	2000-04-13	2008-12-16	Corixa Corporation	Composiciones inmunoestimulantes que comprenden un fosfato de aminoalquil glucosaminida y qs-21.
ATE513913T1 (de) *	2000-05-10	2011-07-15	Sanofi Pasteur Ltd	Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
AUPQ761200A0 (en)	2000-05-19	2000-06-15	Hunter Immunology Limited	Compositions and methods for treatment of mucosal infections
EP2230253B1 (en) *	2000-06-05	2013-08-07	The Brigham & Women's Hospital, Inc.	Antibodies against a homologue of the MDR p-glycoprotein on chromosome 7p15-21 and uses thereof
AU6867801A (en)	2000-06-20	2002-01-02	Corixa Corp	Fusion proteins of mycobacterium tuberculosis
KR100831139B1 (ko)	2000-10-18	2008-05-20	글락소스미스클라인 바이오로지칼즈 에스.에이.	백신
IL155282A0 (en) *	2000-10-18	2003-11-23	Glaxosmithkline Biolog Sa	Vaccines
GB0109297D0 (en)	2001-04-12	2001-05-30	Glaxosmithkline Biolog Sa	Vaccine
US8921534B2 (en)	2001-12-12	2014-12-30	Sanofi Pasteur Limited	Enhancement of the immune response using CD36-binding domain
ES2356154T3 (es)	2003-07-21	2011-04-05	Transgene S.A.	Citoquinas multifuncionales.
US20060257880A1 (en) *	2003-08-29	2006-11-16	The Nottingham Trent University	Gastric and prostate cancer associated antigens
EP2481422A3 (en) *	2003-09-03	2013-04-03	Dendritherapeutics, Inc.	Multiplex vaccines
GB0321615D0 (en)	2003-09-15	2003-10-15	Glaxo Group Ltd	Improvements in vaccination
GB0409940D0 (en) *	2004-05-04	2004-06-09	Glaxosmithkline Biolog Sa	Vaccine
EP2392347A3 (en)	2005-03-31	2012-01-18	GlaxoSmithKline Biologicals S.A.	Vaccines against chlamydial infection
EP1877426B1 (en)	2005-04-29	2012-02-01	GlaxoSmithKline Biologicals SA	Method for preventing or treating m tuberculosis infection
JP5442251B2 (ja) *	2005-05-26	2014-03-12	サイトスバイオテクノロジーアーゲー	拡張可能な発酵方法
US7700567B2 (en)	2005-09-29	2010-04-20	Supergen, Inc.	Oligonucleotide analogues incorporating 5-aza-cytosine therein
CA2630023A1 (en) *	2005-11-14	2007-05-18	Universite Laval	Cancer antigen mage-a9 and uses thereof
TWI457133B (zh)	2005-12-13	2014-10-21	Glaxosmithkline Biolog Sa	新穎組合物
JP5170976B2 (ja) *	2006-04-11	2013-03-27	株式会社イミュノフロンティア	タンパク質複合体およびその製造方法
EP2392675A1 (en)	2006-06-02	2011-12-07	GlaxoSmithKline Biologicals S.A.	Method for identifying whether a patient will be responder or not to immunotherapy based on the differential expression of the IFNG gene
GB0612342D0 (en) *	2006-06-21	2006-08-02	Glaxosmithkline Biolog Sa	Method
ES2657392T3 (es)	2006-09-26	2018-03-05	Infectious Disease Research Institute	Composición de vacuna que contiene un adyuvante sintético
US20090181078A1 (en)	2006-09-26	2009-07-16	Infectious Disease Research Institute	Vaccine composition containing synthetic adjuvant
GB0700284D0 (en) *	2007-01-08	2007-02-14	Glaxosmithkline Biolog Sa	Combination therapy
EA016326B1 (ru) *	2007-01-15	2012-04-30	Глаксосмитклайн Байолоджикалс С.А.	Вакцина
WO2009033807A2 (en) *	2007-09-11	2009-03-19	Mondobiotech Laboratories Ag	Therapeutic uses of b-type natriuretic peptide and human growth hormone 1-43
RU2010114023A (ru) *	2007-09-11	2011-10-20	Мондобайотек Лабораториз Аг (Li)	ПРИМЕНЕНИЕ ПЕПТИДА Asn-Asp-Asp-Cys-Glu-Leu-Cys-Val-Asn-Val-Ala-Cys-Thr-Gly-Cys-Leu-OH В КАЧЕСТВЕ ТЕРАПЕВТИЧЕСКОГО СРЕДСТВА
US9050280B2 (en) *	2007-09-17	2015-06-09	Mdxhealth Sa	Methylation detection of MGMT
CA2702871A1 (en) *	2007-10-19	2009-04-23	Novartis Ag	Meningococcal vaccine formulations
BRPI1009873A2 (pt)	2009-03-17	2016-03-08	Glaxosmithkline Biolog Sa	detecção aperfeiçoada de expressão gênica
PE20120400A1 (es)	2009-05-27	2012-05-04	Glaxosmithkline Biolog Sa	Contrucciones de casb7439
PT2437753T (pt)	2009-06-05	2016-11-23	Infectious Disease Res Inst	Adjuvantes lipídicos de glucopiranosilo sintéticos e composições de vacina contendo os mesmos
GB0910046D0 (en)	2009-06-10	2009-07-22	Glaxosmithkline Biolog Sa	Novel compositions
GB0917457D0 (en)	2009-10-06	2009-11-18	Glaxosmithkline Biolog Sa	Method
US8932600B2 (en)	2010-01-27	2015-01-13	Glaxosmithkline Biologicals S.A.	Modified tuberculosis antigens
GB201022007D0 (en)	2010-12-24	2011-02-02	Imp Innovations Ltd	DNA-sensor
CA2826920A1 (en)	2011-02-15	2012-08-23	Immune Design Corp.	Methods for enhancing immunogen specific immune responses by vectored vaccines
BRPI1100857A2 (pt) *	2011-03-18	2013-05-21	Alexandre Eduardo Nowill	agente imunomodulador e suas combinaÇÕes, seu uso e mÉtodo imunoterÁpico para a recontextualizaÇço, reprogramaÇço e reconduÇço do sistema imune em tempo real
EP3632463A1 (en)	2011-04-08	2020-04-08	Immune Design Corp.	Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
CN102251034B (zh) *	2011-07-05	2012-11-21	北京大学人民医院	基于mage-c2/ct10基因辅助诊断多发性骨髓瘤患者的定量检测试剂盒
UA116528C2 (uk)	2011-08-30	2018-04-10	Астекс Фармасьютікалз, Інк.	Склад, набір, фармацевтична композиція, що містять похідні децитабіну, їх отримання і застосування
GB201116248D0 (en)	2011-09-20	2011-11-02	Glaxosmithkline Biolog Sa	Liposome production using isopropanol
CA2859799A1 (en) *	2011-12-22	2013-06-27	Glaxosmithkline Llc	Method of treating cancer with magea3 immunotherapeutic with braf inhibitor and/or mek inhibitor
RS58868B1 (sr)	2012-02-07	2019-08-30	Infectious Disease Res Inst	Poboljšane adjuvansne formulacije koje sadrže agoniste tlr4 i postupci upotrebe istih
SMT201800368T1 (it)	2012-05-16	2018-09-13	Immune Design Corp	Vaccini per l'infezione da virus-2 herpes simplex
WO2014066443A1 (en)	2012-10-23	2014-05-01	Emory University	Gm-csf and il-4 conjugates, compositions, and methods related thereto
EP3563836A1 (en)	2013-03-01	2019-11-06	Astex Pharmaceuticals, Inc.	Drug combinations
EP3711768A1 (en)	2013-04-18	2020-09-23	Immune Design Corp.	Gla monotherapy for use in cancer treatment
US9849066B2 (en)	2013-04-24	2017-12-26	Corning Incorporated	Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9463198B2 (en)	2013-06-04	2016-10-11	Infectious Disease Research Institute	Compositions and methods for reducing or preventing metastasis
WO2015092710A1 (en)	2013-12-19	2015-06-25	Glaxosmithkline Biologicals, S.A.	Contralateral co-administration of vaccines
IL310015B1 (en)	2013-12-31	2025-10-01	Access To Advanced Health Inst	Single vial formulation
MX375123B (es)	2014-02-14	2025-03-06	Immune Design Corp	Composición para usarse en mejorar la respuesta inmune contra el cáncer.
US20170196954A1 (en)	2014-07-15	2017-07-13	Immune Design Corp.	Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector
CN108024535A (zh)	2015-07-02	2018-05-11	大塚制药株式会社	冻干药物组合物
CN105181966B (zh) *	2015-09-02	2017-08-11	南通大学附属医院	一种mage‑a9的用途
KR102566134B1 (ko)	2015-12-07	2023-08-10	삼성전자주식회사	반도체 소자의 3d 프로파일링 시스템 및 이의 동작 방법
WO2017176076A1 (en)	2016-04-06	2017-10-12	Ewha University - Industry Collaboration Foundation	A peptide with ability to penetrate cell membrane
EP3443123B1 (en)	2016-04-11	2021-08-11	Board of Regents, The University of Texas System	Methods and compositions for detecting single t cell receptor affinity and sequence
EP4112638A1 (en)	2016-05-16	2023-01-04	Access to Advanced Health Institute	Formulation containing tlr agonist and methods of use
JP7195147B2 (ja)	2016-05-16	2022-12-23	アクセスツーアドバンストヘルスインスティチュート	Ｐｅｇ化リポソームおよび使用方法
WO2017210364A1 (en)	2016-06-01	2017-12-07	Infectious Disease Research Institute	Nanoalum particles containing a sizing agent
AU2018285694B2 (en)	2017-06-15	2025-04-10	Access To Advanced Health Institute	Nanostructured lipid carriers and stable emulsions and uses thereof
MX2020001233A (es)	2017-08-03	2020-07-20	Otsuka Pharma Co Ltd	Compuesto farmaceutico y metodos de purificacion del mismo.
AU2018330165B2 (en)	2017-09-08	2025-07-17	Access To Advanced Health Institute	Liposomal formulations comprising saponin and methods of use
JP7529265B2 (ja)	2018-04-19	2024-08-06	ベイラーカレッジオブメディスン	ＣＤ８ａｂおよびクラス１制限Ｔ細胞受容体の強制発現による細胞傷害性ＣＤ８細胞へのＣＤ４Ｔ細胞の再プログラミング
EP3883955A1 (en)	2018-11-19	2021-09-29	Board of Regents, The University of Texas System	A modular, polycistronic vector for car and tcr transduction
CA3121027A1 (en)	2018-11-28	2020-06-04	Board Of Regents, The University Of Texas System	Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
WO2020112493A1 (en)	2018-11-29	2020-06-04	Board Of Regents, The University Of Texas System	Methods for ex vivo expansion of natural killer cells and use thereof
BR112021023726A2 (pt)	2019-05-25	2022-02-15	Infectious Disease Res Inst	Composição e método para secagem por pulverização de uma emulsão de vacina adjuvante
EP4107173A1 (en)	2020-02-17	2022-12-28	Board of Regents, The University of Texas System	Methods for expansion of tumor infiltrating lymphocytes and use thereof
CN116057067A (zh) *	2020-04-17	2023-05-02	弗朗西斯·克里克研究所有限公司	用于治疗黑素瘤的ctl抗原的融合蛋白
WO2022051022A1 (en)	2020-09-04	2022-03-10	Infectious Disease Research Institute	Co-lyophilized rna and nanostructured lipid carrier
CA3173951A1 (en)	2020-09-04	2022-03-10	Emily VOIGT	Genetically-adjuvanted rna vaccines
CA3201499A1 (en)	2020-11-13	2022-05-19	Catamaran Bio, Inc.	Genetically modified natural killer cells and methods of use thereof
WO2022115611A1 (en)	2020-11-25	2022-06-02	Catamaran Bio, Inc.	Cellular therapeutics engineered with signal modulators and methods of use thereof
JP2024501949A (ja)	2020-12-23	2024-01-17	アクセスツーアドバンストヘルスインスティチュート	ソラネソールワクチンアジュバント及びその調製方法
EP4326293A4 (en)	2021-04-22	2025-03-12	Baylor College of Medicine	METHODS FOR MODIFYING IMMUNE CELLS HAVING REDUCED FRATRICIDAL ACTIVITY
EP4169513A1 (en)	2021-10-19	2023-04-26	GlaxoSmithKline Biologicals S.A.	Adjuvant composition comprising sting agonists
WO2023089556A1 (en)	2021-11-22	2023-05-25	Pfizer Inc.	Reducing risk of antigen mimicry in immunogenic medicaments
EP4514382A1 (en)	2022-04-28	2025-03-05	Musc Foundation for Research Development	Chimeric antigen receptor modified regulatory t cells for treating cancer
AU2023336224A1 (en)	2022-09-09	2025-03-27	Access To Advanced Health Institute	Immunogenic vaccine composition incorporating a saponin

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4302386A (en)	1978-08-25	1981-11-24	The Ohio State University	Antigenic modification of polypeptides
US4384995A (en)	1980-01-16	1983-05-24	The Ohio State University	Antigenic modification of polypeptides
US4526716A (en)	1981-11-20	1985-07-02	The Ohio State University	Antigenic modification of polypeptides
US5833975A (en)	1989-03-08	1998-11-10	Virogenetics Corporation	Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
AR241713A1 (es)	1984-08-30	1992-11-30	Smithkline Beckman Corp	Molecula de dna con una secuencia de bases que codifica la proteina c13 y preparacion de vacunas contra la gripe.
ZA896627B (en) *	1988-08-31	1991-03-27	Smithkline Beecham Corp	Vaccinal polypeptides
GB8824496D0 (en)	1988-10-19	1988-11-23	Beecham Group Plc	Process
US6780407B1 (en)	1989-03-08	2004-08-24	Aventis Pasteur	Pox virus comprising DNA sequences encoding CEA and B7 antigen
CA2022752C (en) *	1989-08-11	1998-07-07	Naomi Kitamura	Hepatic parenchymal cell growth factor, gene encoding the same, process for producing the factor, and transformants producing the factor
GB8927546D0 (en)	1989-12-06	1990-02-07	Ciba Geigy	Process for the production of biologically active tgf-beta
SE466259B (sv)	1990-05-31	1992-01-20	Arne Forsgren	Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
ES2055611T3 (es)	1990-07-23	1994-08-16	Zymogenetics Inc	Pdgf resistente a proteasas y metodos de uso.
US6235525B1 (en)	1991-05-23	2001-05-22	Ludwig Institute For Cancer Research	Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
US5925729A (en)	1991-05-23	1999-07-20	Ludwig Institute For Cancer Research	Tumor rejection antigen precursors, tumor rejection antigens and uses thereof
US5541104A (en)	1991-05-23	1996-07-30	Ludwig Institute For Cancer Research	Monoclonal antibodies which bind to tumor rejection antigen precursor mage-1
US5342774A (en)	1991-05-23	1994-08-30	Ludwig Institute For Cancer Research	Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
AU3071592A (en) *	1991-11-14	1993-06-15	Brigham And Women's Hospital	Nitrosylation of protein sh groups and amino acid residues as a therapeutic modality
GB9213559D0 (en)	1992-06-25	1992-08-12	Smithkline Beecham Biolog	Vaccines
CA2138997C (en)	1992-06-25	2003-06-03	Jean-Paul Prieels	Vaccine composition containing adjuvants
WO1994005304A1 (en)	1992-08-31	1994-03-17	Ludwig Institute For Cancer Research	Isolated nonapeptide derived from mage-3 gene and presented by hla-a1, and uses thereof
AU702517B2 (en) *	1993-08-06	1999-02-25	Epimmune, Inc.	Cloning and characterization of the complete MAGE-1 gene
GB9326253D0 (en)	1993-12-23	1994-02-23	Smithkline Beecham Biolog	Vaccines
ATE209690T1 (de)	1994-03-01	2001-12-15	Ludwig Inst Cancer Res	Bestimmung krebsartiger beschaffenheiten durch die genexpression eines mitgliedes der melanomartigengruppe, mage
US5879687A (en) *	1994-04-22	1999-03-09	Corixa Corporation	Methods for enhancement of protective immune responses
DK0772619T4 (da)	1994-07-15	2011-02-21	Univ Iowa Res Found	Immunmodulatoriske oligonukleotider
JPH10511639A (ja) *	1994-09-30	1998-11-10	ルードヴィッヒ・インスティテュート・フォア・キャンサー・リサーチ	腫瘍拒絶抗原前駆体または腫瘍拒絶抗原を含有する組成物ならびにアジュバント及び／又は成長因子
US5612030A (en) *	1995-01-17	1997-03-18	University Of Kentucky Research Foundation	Anti-idiotype monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
US6017705A (en)	1995-03-14	2000-01-25	Ludwig Institute For Cancer Research	Isolated nucleic acid molecules which are members of the MAGE-B family and uses thereof
UA56132C2 (uk)	1995-04-25	2003-05-15	Смітклайн Бічем Байолоджікалс С.А.	Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
CA2224662A1 (en)	1995-06-29	1997-01-16	Ludwig Institute For Cancer Research	Isolated nucleic acid molecule which encodes murine tumor rejection antigen precursor smage-3
AU7440196A (en)	1995-10-12	1997-04-30	Chiron Corporation	Baboon mage-3 homologs, dna encoding the homologs, and a process for their use
US6265215B1 (en)	1996-09-13	2001-07-24	Ludwig Institute For Cancer Research	Isolated peptides which complex with HLA-Cw16 and uses thereof
US5908778A (en)	1996-10-03	1999-06-01	Ludwig Institute For Cancer Research	Mage-10 encoding cDNA, the tumor rejection antigen precursor mage-10, antibodies specific to the molecule, and uses thereof
US6030780A (en)	1996-10-15	2000-02-29	The Rockefeller University	Purified Stat proteins and methods of purifying thereof
WO1998020165A2 (en)	1996-11-06	1998-05-14	Whitehead Institute For Biomedical Research	Biallelic markers
US7157089B1 (en)	1996-11-26	2007-01-02	Stressgen Biotechnologies Corporation	Immune responses using compositions containing stress proteins
WO1998026747A2 (en)	1996-12-17	1998-06-25	Terman David S	Superantigen based methods and compositions for treatment of diseases
US6287569B1 (en)	1997-04-10	2001-09-11	The Regents Of The University Of California	Vaccines with enhanced intracellular processing
US6680191B1 (en)	1997-04-25	2004-01-20	Ludwig Institute For Cancer	Isolated nucleic acid molecules coding for tumor rejection antigen precursors of members of the MAGE-C and MAGE-B FAMILIES and uses thereof
US20020176865A1 (en)	1997-04-25	2002-11-28	Sophie Lucas	Isolated nucleic acid molecules coding for tumor rejection antigen precursors of members of the MAGE-C and MAGE-B families and uses thereof
US6027924A (en)	1997-04-25	2000-02-22	Ludwig Institute For Cancer Research	Isolated nucleic acid molecule coding for tumor rejection antigen precursor MAGE-C1 and uses thereof
US6043084A (en)	1997-10-10	2000-03-28	Ludwig Institute For Cancer Research	Isolated nucleic acid molecules associated with colon cancer and methods for diagnosing and treating colon cancer
US6291430B1 (en) *	1997-09-12	2001-09-18	Ludwig Institute For Cancer Research	Mage-3 peptides presented by HLA class II molecules
US6716809B1 (en)	1997-09-12	2004-04-06	Ludwig Institute For Cancer Research	Mage-A3 peptides presented by HLA class molecules
US5965535A (en)	1997-09-12	1999-10-12	Ludwig Institute For Cancer Research	Mage-3 peptides presented by HLA class II molecules
CN1227360C (zh)	1998-02-05	2005-11-16	史密丝克莱恩比彻姆生物有限公司	Mage家族肿瘤相关抗原衍生物及其编码核酸序列
EP1068354A2 (en)	1998-04-09	2001-01-17	Whitehead Institute For Biomedical Research	Biallelic markers
US6686147B1 (en)	1998-07-15	2004-02-03	Ludwig Institute For Cancer Research	Cancer associated antigens and uses therefor

1999
- 1999-02-02 CN CNB998046043A patent/CN1227360C/zh not_active Expired - Fee Related
- 1999-02-02 AU AU27220/99A patent/AU737337B2/en not_active Ceased
- 1999-02-02 DK DK05076599.9T patent/DK1584685T3/da active
- 1999-02-02 KR KR1020067008476A patent/KR100824105B1/ko not_active Expired - Fee Related
- 1999-02-02 CZ CZ20002869A patent/CZ298364B6/cs not_active IP Right Cessation
- 1999-02-02 CZ CZ20060442A patent/CZ298347B6/cs not_active IP Right Cessation
- 1999-02-02 EP EP06075363A patent/EP1659179B1/en not_active Expired - Lifetime
- 1999-02-02 ES ES99907476T patent/ES2255248T3/es not_active Expired - Lifetime
- 1999-02-02 DK DK06075363.9T patent/DK1659179T3/da active
- 1999-02-02 WO PCT/EP1999/000660 patent/WO1999040188A2/en not_active Ceased
- 1999-02-02 ES ES06075362T patent/ES2342416T3/es not_active Expired - Lifetime
- 1999-02-02 JP JP2000530602A patent/JP4768121B2/ja not_active Expired - Fee Related
- 1999-02-02 DK DK99907476T patent/DK1053325T3/da active
- 1999-02-02 AT AT06075362T patent/ATE462788T1/de active
- 1999-02-02 PT PT99907476T patent/PT1053325E/pt unknown
- 1999-02-02 AT AT99907476T patent/ATE315088T1/de active
- 1999-02-02 CA CA2584482A patent/CA2584482C/en not_active Expired - Fee Related
- 1999-02-02 KR KR1020007008550A patent/KR100633212B1/ko not_active Expired - Fee Related
- 1999-02-02 CA CA2319309A patent/CA2319309C/en not_active Expired - Fee Related
- 1999-02-02 PT PT06075363T patent/PT1659179E/pt unknown
- 1999-02-02 HU HU0102639A patent/HU228467B1/hu not_active IP Right Cessation
- 1999-02-02 SI SI9931053T patent/SI1584685T1/sl unknown
- 1999-02-02 TR TR2000/02284T patent/TR200002284T2/xx unknown
- 1999-02-02 PT PT06075362T patent/PT1659178E/pt unknown
- 1999-02-02 AT AT06075363T patent/ATE513042T1/de active
- 1999-02-02 DE DE69943359T patent/DE69943359D1/de not_active Expired - Lifetime
- 1999-02-02 EP EP99907476A patent/EP1053325B1/en not_active Expired - Lifetime
- 1999-02-02 SI SI9930879T patent/SI1053325T1/sl unknown
- 1999-02-02 DE DE69929310T patent/DE69929310T2/de not_active Expired - Lifetime
- 1999-02-02 AT AT05076599T patent/ATE505542T1/de active
- 1999-02-02 SI SI9931044T patent/SI1659178T1/sl unknown
- 1999-02-02 BR BRPI9907691-8A patent/BR9907691B1/pt not_active IP Right Cessation
- 1999-02-02 DK DK06075362.1T patent/DK1659178T3/da active
- 1999-02-02 EP EP06075362A patent/EP1659178B1/en not_active Expired - Lifetime
- 1999-02-02 PT PT05076599T patent/PT1584685E/pt unknown
- 1999-02-02 IL IL13744299A patent/IL137442A0/xx active IP Right Grant
- 1999-02-02 EP EP05076599A patent/EP1584685B1/en not_active Expired - Lifetime
- 1999-02-02 NZ NZ506086A patent/NZ506086A/xx not_active IP Right Cessation
- 1999-02-02 DE DE69942214T patent/DE69942214D1/de not_active Expired - Lifetime
- 1999-02-02 SI SI9931061T patent/SI1659179T1/sl unknown
- 1999-02-04 AR ARP990100475A patent/AR018064A1/es active IP Right Grant
- 1999-02-12 TW TW088102224A patent/TWI238853B/zh not_active IP Right Cessation
- 1999-05-16 SA SA99200126A patent/SA99200126B1/ar unknown
2000
- 2000-07-21 IL IL137442A patent/IL137442A/en not_active IP Right Cessation
- 2000-08-04 NO NO20003958A patent/NO328507B1/no not_active IP Right Cessation
2006
- 2006-03-07 CY CY20061100310T patent/CY1105685T1/el unknown
- 2006-11-02 IL IL179010A patent/IL179010A0/en unknown
2008
- 2008-01-17 IL IL188875A patent/IL188875A/en not_active IP Right Cessation
2009
- 2009-04-27 NO NO20091665A patent/NO331719B1/no not_active IP Right Cessation
- 2009-05-18 JP JP2009120409A patent/JP2009201510A/ja active Pending
- 2009-12-17 US US12/640,306 patent/US8097257B2/en not_active Expired - Fee Related
2010
- 2010-03-12 US US12/722,691 patent/US8044183B2/en not_active Expired - Fee Related
- 2010-06-10 CY CY20101100509T patent/CY1110180T1/el unknown
2011
- 2011-07-08 CY CY20111100663T patent/CY1111672T1/el unknown
- 2011-09-14 CY CY20111100885T patent/CY1111831T1/el unknown
- 2011-12-13 US US13/324,509 patent/US8597656B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CA2584482C (en)	2012-03-27
IL179010A0 (en)	2007-03-08
SI1659178T1 (sl)	2010-07-30
HK1093522A1 (en)	2007-03-02
DK1659178T3 (da)	2010-07-12
EP1659178B1 (en)	2010-03-31
JP2002502604A (ja)	2002-01-29
CN1295616A (zh)	2001-05-16
EP1053325B1 (en)	2006-01-04
DE69929310T2 (de)	2006-08-03
TWI238853B (en)	2005-09-01
US8044183B2 (en)	2011-10-25
US20120269835A1 (en)	2012-10-25
HUP0102639A3 (en)	2004-04-28
PT1053325E (pt)	2006-05-31
CY1105685T1 (el)	2010-12-22
HK1033838A1 (en)	2001-09-28
US20100204458A1 (en)	2010-08-12
PT1584685E (pt)	2011-06-17
CZ298364B6 (cs)	2007-09-05
NO331719B1 (no)	2012-03-05
HUP0102639A1 (hu)	2001-11-28
AU737337B2 (en)	2001-08-16
JP2009201510A (ja)	2009-09-10
KR20060067977A (ko)	2006-06-20
KR20010040675A (ko)	2001-05-15
WO1999040188A3 (en)	1999-10-14
US8097257B2 (en)	2012-01-17
EP1659179A3 (en)	2007-01-17
NO20003958L (no)	2000-10-04
SI1053325T1 (sl)	2006-06-30
NO20091665L (no)	2000-10-04
EP1053325A2 (en)	2000-11-22
ES2342416T3 (es)	2010-07-06
KR100633212B1 (ko)	2006-10-11
NO328507B1 (no)	2010-03-08
SI1584685T1 (sl)	2011-07-29
CA2319309A1 (en)	1999-08-12
ES2255248T3 (es)	2006-06-16
PT1659179E (pt)	2011-09-16
PL342852A1 (en)	2001-07-16
ATE505542T1 (de)	2011-04-15
TR200002284T2 (tr)	2000-11-21
JP4768121B2 (ja)	2011-09-07
EP1584685A3 (en)	2005-12-07
ATE462788T1 (de)	2010-04-15
CA2584482A1 (en)	1999-08-12
DK1659179T3 (da)	2011-10-10
CZ20002869A3 (cs)	2001-01-17
EP1659179B1 (en)	2011-06-15
CY1110180T1 (el)	2015-01-14
AR018064A1 (es)	2001-10-31
CA2319309C (en)	2010-08-10
DK1053325T3 (da)	2006-05-22
EP1659178A3 (en)	2007-01-17
CN1227360C (zh)	2005-11-16
IL137442A0 (en)	2001-07-24
ATE315088T1 (de)	2006-02-15
IL188875A0 (en)	2009-02-11
DE69942214D1 (de)	2010-05-12
US8597656B2 (en)	2013-12-03
HK1083026A1 (en)	2006-06-23
NO20003958D0 (no)	2000-08-04
DE69943359D1 (de)	2011-05-26
EP1584685B1 (en)	2011-04-13
US20100209444A1 (en)	2010-08-19
NZ506086A (en)	2003-01-31
PT1659178E (pt)	2010-06-28
SA99200126B1 (ar)	2006-08-20
HK1093521A1 (en)	2007-03-02
EP1659178A2 (en)	2006-05-24
EP1659179A2 (en)	2006-05-24
BR9907691A (pt)	2000-11-14
CY1111672T1 (el)	2015-10-07
EP1584685A2 (en)	2005-10-12
IL188875A (en)	2011-08-31
IL137442A (en)	2008-04-13
DK1584685T3 (da)	2011-07-11
SI1659179T1 (sl)	2011-10-28
ATE513042T1 (de)	2011-07-15
CY1111831T1 (el)	2015-10-07
DE69929310D1 (de)	2006-03-30
WO1999040188A2 (en)	1999-08-12
CZ298347B6 (cs)	2007-09-05
HU228467B1 (en)	2013-03-28
AU2722099A (en)	1999-08-23
KR100824105B1 (ko)	2008-04-21

Publication	Publication Date	Title
BR9907691B1 (pt)	2011-05-31	derivado de antìgeno e antìgeno da famìlia mage associado a tumor, seqüência de ácido nucléico, codificando os mesmos, seus usos na preparação de vacina, processo para produção de vacina e vacina.
BR9911914B1 (pt)	2010-10-19	n-arilamidas do ácido sulfonilaminocarboxìlico substituìdas por enxofre, processo para sua preparação, bem como preparações farmacêuticas que compreendem as mesmas.
BRPI9917862B1 (pt)	2013-05-07	dihidropirimidinas, bem como processo para a preparaÇço e aplicaÇço das mesmas.
BR9915545B1 (pt)	2013-08-06	composição de vacina, processo para preparação da mesma e kit compreendendo dois recipientes.
WO1999052503A3 (en)	2001-05-10	Rna cancer vaccine and methods for its use
FI954536L (fi)	1995-09-25	Eristettyjä nukleiinihappomolekyylejä, jotka koodittavat kasvainhyljintäantigeenin esiastetta MAGE-3, ja niiden hyötykäyttö
BR9813857B1 (pt)	2013-11-12	Processo para a preparação de um desinfetante aquoso, e, desinfetante aquoso.
MXPA03000574A (es)	2003-06-06	Vidrios ceramizados, proceso para su preparacion y uso.
BR0015831B1 (pt)	2010-06-15	aplicação de silicatos de estrutura salinos, silicato de estrutura salino, processo para a preparação do mesmo, bem como toner, pó ou laca em pó eletrofotográfico.
BR9801181B1 (pt)	2009-05-05	gênero alimentìcio fortificado com cálcio, bem como processo para preparação do mesmo.
BR9711318B1 (pt)	2009-01-13	processo para preparar intermediÁrios para florfenicol.
BR0008984B1 (pt)	2013-05-28	alimento tipo aperitivo, e, processo para preparaÇço de alimento tipo aperitivo.
DK317288D0 (da)	1988-06-10	Hybridprotein af humant protein c og dets fremstilling samt dna, som koder det
WO2003039225A3 (en)	2004-03-04	Antigen arrays comprising rankl for treatment of bone disease
BR0100188B1 (pt)	2009-05-05	cabelo artificial para implante e processo para produção de cabelo artificial.
AR010069A1 (es)	2000-05-15	Metodo para la manufactura de metoprolol, metoprolol obtenido por dicho metodo y metodo para la manufactura de una preparacion farmaceutica
ZA975588B (en)	1998-01-23	Isolated nucleic acid molecules which code for gage tumor rejection antigen, the tumor rejection antigen, and uses thereof.
FI970071A7 (fi)	1997-01-07	Eristetty nukleiinihapposekvenssi, joka koodaa HLA-A2:n esittämää tuum orihyljintäantigeeniä
BR9805329B1 (pt)	2009-05-05	catalisador, processo para a preparação o catalisador e processo para a preparação de acetato de vinila sob aplicação do catalisador.
WO2003049765A3 (en)	2003-10-02	Enveloped virus vaccine and method for production
BR8705716A (pt)	1988-05-31	Estirilariloxi-eter-sulfonatos,processo para sua preparacao e sua aplicacao,bem como combinacoes tenso-ativas
FR2813886B1 (fr)	2005-04-15	Resines novolaques, leur procede de preparation et leurs utilisations
WO2001004143A3 (en)	2001-10-11	Prostase vaccine
PT1053224E (pt)	2002-12-31	Bifenilsulfonilcianamida, processo para a sua preparacao e sua utilizacao como medicamento
WO1997013858A3 (en)	1997-06-05	Baboon mage-3 homologs, dna encoding the homologs, and a process for their use

Legal Events

Date	Code	Title	Description
2009-02-10	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2010-09-08	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2011-05-31	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 31/05/2011, OBSERVADAS AS CONDICOES LEGAIS.
2016-04-26	B21F	Lapse acc. art. 78, item iv - on non-payment of the annual fees in time	Free format text: REFERENTE A 17A ANUIDADE.
2016-08-23	B24J	Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)	Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2364 DE 26-04-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.